Nashville, TN

Nashville, Tennessee 37203

1 studies enrolling now · 5 studies all time

What they study most

Advanced Solid Tumors, Branch Retinal Vein Occlusion (BRVO), Diabetic Macular Edema (DME), Lymphoma, Neovascular Age-Related Macular Degeneration (NVAMD), Neovascular Age-related Macular Degeneration (NVAMD)

Studies at this site

• A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO — Recruiting now
• A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME — Running, not enrolling
• A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME — Running, not enrolling
• A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) — Completed
• Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma — Completed